Calabria

In Calabria region 56% of women (aged 24-64) are screened regularly, meaning every 3 years. The analysis on cross-protective activity exercised by bivalent and quadrivalent vaccines shows that the bivalent vaccine could prevent more pre-cancerous lesions and cases of cervicocarcinoma than quadrivale...

Full description

Bibliographic Details
Main Authors: Roberto Gasparini, Donatella Panatto, Bruna Dirodi, Rosa Prato, Gianni Amunni, Valter Turello, Luigi Sudano, Paolo Cristoforoni, Sara Boccalini, Paolo Bonanni
Format: Article
Language:English
Published: SEEd Medical Publishers 2012-11-01
Series:Farmeconomia: Health Economics and Therapeutic Pathways
Subjects:
hpv
Online Access:https://journals.seedmedicalpublishers.com/index.php/FE/article/view/453
id doaj-a1ee2691983e4694bff23e5fefe0992e
record_format Article
spelling doaj-a1ee2691983e4694bff23e5fefe0992e2020-11-25T02:19:34ZengSEEd Medical PublishersFarmeconomia: Health Economics and Therapeutic Pathways2240-256X2012-11-01132S252710.7175/fe.v13i2S.453418CalabriaRoberto Gasparini0Donatella Panatto1Bruna Dirodi2Rosa Prato3Gianni Amunni4Valter Turello5Luigi Sudano6Paolo Cristoforoni7Sara Boccalini8Paolo Bonanni9Dipartimento di Scienze della Salute, Università di GenovaDipartimento di Scienze della Salute, Università di GenovaDirezione Access to Medicine, GlaxoSmithKline, VeronaDipartimento di Scienze Mediche e Chirurgiche, Università degli Studi di FoggiaDipartimento di Ginecologia, Perinatologia e Riproduzione Umana, Università di FirenzeDipartimento di Prevenzione U.O. Igiene e Sanità Pubblica, Azienda USL 3 GenovaAssessorato Sanità, Salute e Politiche Sociali, Servizio Igiene, Sanità Pubblica, Veterinaria e degli Ambienti di lavoroDipartimento di Oncologia Ginecologica, Istituto Nazionale per la Ricerca sul Cancro, GenovaDipartimento di Sanità Pubblica, Università di FirenzeDipartimento di Sanità Pubblica, Università di FirenzeIn Calabria region 56% of women (aged 24-64) are screened regularly, meaning every 3 years. The analysis on cross-protective activity exercised by bivalent and quadrivalent vaccines shows that the bivalent vaccine could prevent more pre-cancerous lesions and cases of cervicocarcinoma than quadrivalent, and that the latter could prevent genital warts that are not prevented by bivalent. The major number of cases avoided by the bivalent make it possible to fully offset the cost savings related to warts associated with the quadrivalent vaccine. Furthermore, a cost-effectiveness analysis shows that, considering regional tariffs, the multiple cohort (12-year-old + 25-year-old women) vaccination strategy with a 90% coverage could prevent 37 cases of cervicocarcinoma and 17 related deaths more than the vaccination of only 12-year-old girls, and thus proves to be cost-effective (9,767 €/QALY).https://journals.seedmedicalpublishers.com/index.php/FE/article/view/453hpvvaccination strategyscreeningcalabriacost-effectiveness analysis
collection DOAJ
language English
format Article
sources DOAJ
author Roberto Gasparini
Donatella Panatto
Bruna Dirodi
Rosa Prato
Gianni Amunni
Valter Turello
Luigi Sudano
Paolo Cristoforoni
Sara Boccalini
Paolo Bonanni
spellingShingle Roberto Gasparini
Donatella Panatto
Bruna Dirodi
Rosa Prato
Gianni Amunni
Valter Turello
Luigi Sudano
Paolo Cristoforoni
Sara Boccalini
Paolo Bonanni
Calabria
Farmeconomia: Health Economics and Therapeutic Pathways
hpv
vaccination strategy
screening
calabria
cost-effectiveness analysis
author_facet Roberto Gasparini
Donatella Panatto
Bruna Dirodi
Rosa Prato
Gianni Amunni
Valter Turello
Luigi Sudano
Paolo Cristoforoni
Sara Boccalini
Paolo Bonanni
author_sort Roberto Gasparini
title Calabria
title_short Calabria
title_full Calabria
title_fullStr Calabria
title_full_unstemmed Calabria
title_sort calabria
publisher SEEd Medical Publishers
series Farmeconomia: Health Economics and Therapeutic Pathways
issn 2240-256X
publishDate 2012-11-01
description In Calabria region 56% of women (aged 24-64) are screened regularly, meaning every 3 years. The analysis on cross-protective activity exercised by bivalent and quadrivalent vaccines shows that the bivalent vaccine could prevent more pre-cancerous lesions and cases of cervicocarcinoma than quadrivalent, and that the latter could prevent genital warts that are not prevented by bivalent. The major number of cases avoided by the bivalent make it possible to fully offset the cost savings related to warts associated with the quadrivalent vaccine. Furthermore, a cost-effectiveness analysis shows that, considering regional tariffs, the multiple cohort (12-year-old + 25-year-old women) vaccination strategy with a 90% coverage could prevent 37 cases of cervicocarcinoma and 17 related deaths more than the vaccination of only 12-year-old girls, and thus proves to be cost-effective (9,767 €/QALY).
topic hpv
vaccination strategy
screening
calabria
cost-effectiveness analysis
url https://journals.seedmedicalpublishers.com/index.php/FE/article/view/453
work_keys_str_mv AT robertogasparini calabria
AT donatellapanatto calabria
AT brunadirodi calabria
AT rosaprato calabria
AT gianniamunni calabria
AT valterturello calabria
AT luigisudano calabria
AT paolocristoforoni calabria
AT saraboccalini calabria
AT paolobonanni calabria
_version_ 1724875844279599104